The long-term management of bipolar disorders with lithium, carbamazepine, and antidepressants.
The long-term management of bipolar disorders with lithium, carbamazepine, and antidepressants.
复制标题
使用锂、卡马西平和抗抑郁药长期治疗双相情感障碍。
DOI：
--
复制
发表时间：
1985
影响因子：
5.3
通讯作者：
H. Kravitz
中科院分区：
文献类型：
--
作者：
J. Fawcett;H. Kravitz
卡马西平在治疗锂治疗无效的双相情感障碍患者方面获得了认可，成为一种有价值的药物。本文介绍了90例双相患者的临床治疗经验：48%的患者对锂单独治疗或与其他标准药物联合治疗有效。34名锂盐无反应者接受卡马西平治疗，其中17人(50%)对卡马西平有反应，5人对卡马西平加锂有反应，总有效率为65%。讨论了副作用、血药浓度和依从性等问题。这些观察结果支持卡马西平的有效性和安全性，并表明有必要进行良好控制的双盲研究。
Carbamazepine is gaining recognition as a valuable drug in the treatment of patients with bipolar disorders who fail to respond to lithium. Clinical experience in the treatment of 90 bipolar patients is described: 48% responded to lithium alone or in combination with other standard drug treatments. A subgroup of 34 lithium nonresponders were treated with carbamazepine; of these, 17 (50%) responded to carbamazepine and 5 responded to carbamazepine plus lithium, for a total response rate of 65%. Issues of side effects, blood levels, and compliance are discussed. These observations support the efficacy and safety of carbamazepine and suggest the need for well-controlled double-blind studies.